Current and Emerging Biologic Therapies for Severe Asthma

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Severe asthma is a complex, heterogeneous condition with persistent symptoms and exacerbations.
• Current approved monoclonal antibodies target IgE, IL-5, IL-4 receptor α, and TSLP, showing efficacy in reducing exacerbations and corticosteroid use.
• Despite advances, limitations exist for specific asthma phenotypes and airway remodeling.

Purpose of the Study:

• To review the current landscape of approved biologics for severe asthma.
• To discuss the rationale and emerging strategies for next-generation therapies.
• To highlight future directions for precision-targeted treatment in severe asthma.

Main Methods:

• Review of approved monoclonal antibodies and their targets (IgE, IL-5, IL-4Rα, TSLP).
• Analysis of clinical efficacy, safety profiles, and predictors of response.
• Exploration of emerging therapeutic strategies targeting alarmins, cytokine pathways, and B cells.

Main Results:

• Approved biologics offer substantial benefits in exacerbation reduction, lung function, and quality of life.
• Response predictors include blood eosinophil counts, fractional exhaled nitric oxide, and phenotype-specific biomarkers.
• Next-generation therapies aim to address unmet needs in type 2-low and refractory asthma phenotypes.

Conclusions:

• Biologics have transformed severe asthma management, but heterogeneity necessitates further innovation.
• Emerging strategies, including multi-target agents and upstream alarmin inhibitors, promise improved outcomes.
• Biomarker-guided personalized therapy represents the future direction for severe asthma treatment.